BillionToOne is a publicly listed company tracked for investment-relevant business developments.
BillionToOne's synthetic DNA spike-in technology solves PCR amplification noise, enabling ultra-sensitive liquid biopsy for prenatal testing and cancer detection; the company has commercialized prenatal testing (600k tests/year, 20% share) and is advancing a stepwise pipeline from late-stage cancer MRD to early detection and population screening.